Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
celgene 150$
- Creatore Discussione bobol
- Data di inizio
-
Ecco la 66° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.
I principali indici azionari hanno vissuto una settimana turbolenta, caratterizzata dalla riunione della Fed, dai dati macro importanti e dagli utili societari di alcune big tech Usa. Mercoledì scorso la Fed ha confermato i tassi di interesse e ha sostanzialmente escluso un aumento. Tuttavia, Powell e colleghi potrebbero lasciare il costo del denaro su livelli restrittivi in mancanza di progressi sul fronte dei prezzi. Inoltre, i dati di oggi sul mercato del lavoro Usa hanno mostrato dei segnali di raffreddamento. Per continuare a leggere visita il link
Belunat
Nuovo Utente
- Registrato
- 4/10/17
- Messaggi
- 1.005
- Punti reazioni
- 237
Ho le Calgene da luglio 2014,dimenticate nel deposito titoli di una delle sciagurate banche venete;sinceramene non aver venduto sui massimi ora dispiace,ma verrà il tempo!
Sono titoli che seguono poco l'andamento dell'indice,basta una sola notizia tra una trimestrale e l'altra è si va nello spazio o tra gli abissi.
Sono rimansto in sella di Teva dagli oltre 30$,bisognerebbe farsi un target e rispettarlo,gainare o lossare ma non lasciare correre.
Con questi titoli ci si può far male.
Per quel che può servire,al momento il titolo viene dato buy dal gruppo intesa.
Sono titoli che seguono poco l'andamento dell'indice,basta una sola notizia tra una trimestrale e l'altra è si va nello spazio o tra gli abissi.
Sono rimansto in sella di Teva dagli oltre 30$,bisognerebbe farsi un target e rispettarlo,gainare o lossare ma non lasciare correre.
Con questi titoli ci si può far male.
Per quel che può servire,al momento il titolo viene dato buy dal gruppo intesa.
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
Oggi ha voglia di salire, sta passando i 106 
Skorp10
龍 Immortal ad Vitam
- Registrato
- 5/1/10
- Messaggi
- 2.992
- Punti reazioni
- 262
106,50$ odierni....sei sparito, hai fatto bene...
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
Trans77
Hic Sunt Leones
- Registrato
- 28/8/14
- Messaggi
- 6.963
- Punti reazioni
- 713
Bene le chiusure sopra EMA20 nel daily e, auspicando che possa essere un segnale di inversione sul medio/lungo, sopra EMA200 nel weekly.
Dentro da 105, a distanza di quasi 2 anni dalla vendita.
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
Buona l'apertura a 110
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
Oggi tonica, potrebbe confermare nei prossimi giorni
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies
Jan. 7, 2018 6:00 PM
Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera
Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib
A New Drug Application (NDA) submission for fedratinib in myelofibrosis is planned for mid-2018
SUMMIT, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
Fedratinib, a highly selective JAK2 kinase inhibitor, was evaluated in 877 patients across 18 clinical trials. In a randomized, placebo-controlled, phase III pivotal trial (JAKARTA-1) for patients with treatment-naïve myelofibrosis, fedratinib demonstrated statistically significant improvements in the primary and secondary endpoints of splenic response and total symptom score, respectively. In an exploratory subgroup analysis, these improvements were observed regardless of a patient’s baseline platelet count.
A multi-center, single-arm phase II trial (JAKARTA-2) evaluated fedratinib in myelofibrosis patients who were found to be resistant or intolerant to ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor. In this second-line setting, fedratinib demonstrated clinically meaningful improvements in splenic response and total symptom score.
As previously reported, JAKARTA-2 was stopped prematurely due to a clinical hold placed on the fedratinib program by the U.S. Food and Drug Administration (FDA) after potential cases of Wernicke’s encephalopathy (WE) were reported in eight out of 877 patients receiving one or more doses (less than one percent of treated patients). The FDA removed the clinical hold in August 2017.
Based on the reported benefit risk profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018.
“Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “We believe fedratinib is uniquely positioned as a potential treatment for myelofibrosis and it provides strategic options for us to build leadership in this disease with luspatercept and other pipeline assets.”
“We launched Impact Biomedicines and based on our thorough review of the data, fedratinib presents a compelling risk benefit profile in both treatment-naïve patients and patients who are resistant or intolerant to other JAK2 therapies,” said Dr. John Hood, Chief Executive Officer of Impact. “We believe Celgene is the ideal organization to follow through on our mission of maximizing fedratinib’s potential for patients with myelofibrosis.”
Deal Terms
Under the terms of the agreement, Celgene will make an upfront cash payment of approximately $1.1 billion. In addition, Impact Biomedicines’s shareholders are eligible to receive contingent payments based on regulatory approval and sales-based milestones. The maximum aggregate amount payable for regulatory approval milestones is $1.4 billion relating to approvals for myelofibrosis and other indications. Starting from global annual net sales of $1.0 billion, aggregate tiered sales-based milestone payments could total a maximum of $4.5 billion if global annual net sales exceed $5.0 billion.
Jan. 7, 2018 6:00 PM
Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera
Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients resistant or intolerant to ruxolitinib
A New Drug Application (NDA) submission for fedratinib in myelofibrosis is planned for mid-2018
SUMMIT, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
Fedratinib, a highly selective JAK2 kinase inhibitor, was evaluated in 877 patients across 18 clinical trials. In a randomized, placebo-controlled, phase III pivotal trial (JAKARTA-1) for patients with treatment-naïve myelofibrosis, fedratinib demonstrated statistically significant improvements in the primary and secondary endpoints of splenic response and total symptom score, respectively. In an exploratory subgroup analysis, these improvements were observed regardless of a patient’s baseline platelet count.
A multi-center, single-arm phase II trial (JAKARTA-2) evaluated fedratinib in myelofibrosis patients who were found to be resistant or intolerant to ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor. In this second-line setting, fedratinib demonstrated clinically meaningful improvements in splenic response and total symptom score.
As previously reported, JAKARTA-2 was stopped prematurely due to a clinical hold placed on the fedratinib program by the U.S. Food and Drug Administration (FDA) after potential cases of Wernicke’s encephalopathy (WE) were reported in eight out of 877 patients receiving one or more doses (less than one percent of treated patients). The FDA removed the clinical hold in August 2017.
Based on the reported benefit risk profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned beginning in the middle of 2018.
“Myelofibrosis is a disease with high unmet medical need as the number of patients who are ineligible for or become resistant to existing therapy continues to increase,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “We believe fedratinib is uniquely positioned as a potential treatment for myelofibrosis and it provides strategic options for us to build leadership in this disease with luspatercept and other pipeline assets.”
“We launched Impact Biomedicines and based on our thorough review of the data, fedratinib presents a compelling risk benefit profile in both treatment-naïve patients and patients who are resistant or intolerant to other JAK2 therapies,” said Dr. John Hood, Chief Executive Officer of Impact. “We believe Celgene is the ideal organization to follow through on our mission of maximizing fedratinib’s potential for patients with myelofibrosis.”
Deal Terms
Under the terms of the agreement, Celgene will make an upfront cash payment of approximately $1.1 billion. In addition, Impact Biomedicines’s shareholders are eligible to receive contingent payments based on regulatory approval and sales-based milestones. The maximum aggregate amount payable for regulatory approval milestones is $1.4 billion relating to approvals for myelofibrosis and other indications. Starting from global annual net sales of $1.0 billion, aggregate tiered sales-based milestone payments could total a maximum of $4.5 billion if global annual net sales exceed $5.0 billion.
Trans77
Hic Sunt Leones
- Registrato
- 28/8/14
- Messaggi
- 6.963
- Punti reazioni
- 713
Celgene puts shareholders on $7 bln M&A trial
NEW YORK, Jan 8 (Reuters Breakingviews) - Buying privately held cancer specialist Impact Biomedicines may help the biotech giant refillits pipeline after recent drug flops. Insisting on a series of earnouts based on sales reduces risk. But Celgene needs more than a booster shot to cure longer-term ailments.
Full view will be published shortly.
On Twitterhttps://twitter.com/AntonyMCurrie
CONTEXT NEWS
- Celgene (CELG.O) on Jan. 7 said it had agreed to buy Impact Biomedicines for up to $7 billion. The biotechnology giant will pay $1.1 billion in cash up front. Further payments totaling as much as $1.25 billion are dependent on Impact receiving regulatory approvals for its drug designed to combat myelofibrosis. Another $150 million requires approvals for other treatments, including its drug to fight polycythemia.
- Therest of the headline purchase price is linked to Impact's drug sales. The extra payments kick in once global annual net sales hit $1 billion. The maximum sales-related payout is $4.5 billion, which shareholders in privately held Impact will receive if annual net sales top $5 billion.
NEW YORK, Jan 8 (Reuters Breakingviews) - Buying privately held cancer specialist Impact Biomedicines may help the biotech giant refillits pipeline after recent drug flops. Insisting on a series of earnouts based on sales reduces risk. But Celgene needs more than a booster shot to cure longer-term ailments.
Full view will be published shortly.
On Twitterhttps://twitter.com/AntonyMCurrie
CONTEXT NEWS
- Celgene (CELG.O) on Jan. 7 said it had agreed to buy Impact Biomedicines for up to $7 billion. The biotechnology giant will pay $1.1 billion in cash up front. Further payments totaling as much as $1.25 billion are dependent on Impact receiving regulatory approvals for its drug designed to combat myelofibrosis. Another $150 million requires approvals for other treatments, including its drug to fight polycythemia.
- Therest of the headline purchase price is linked to Impact's drug sales. The extra payments kick in once global annual net sales hit $1 billion. The maximum sales-related payout is $4.5 billion, which shareholders in privately held Impact will receive if annual net sales top $5 billion.
Whineeeer
Nuovo Utente
- Registrato
- 8/7/12
- Messaggi
- 537
- Punti reazioni
- 15
mi sembra un deal interessante... 1 miliardo speso oggi, poi se va bene, ne sborsano altri...
ho preso qualche call scadenza gennaio con strike 105 a $1.24, sottostante scambiava attorno ai $101.7
vediamo se nei prossimi giorni si può mediare o ridurre in profitto o se riesco a portarle itm...
Celgene Corporation (CELG) 180119C00105000-CELG-CALL - NASDAQ.com delta attorno allo 0.30
ho preso qualche call scadenza gennaio con strike 105 a $1.24, sottostante scambiava attorno ai $101.7
vediamo se nei prossimi giorni si può mediare o ridurre in profitto o se riesco a portarle itm...
Celgene Corporation (CELG) 180119C00105000-CELG-CALL - NASDAQ.com delta attorno allo 0.30
Whineeeer
Nuovo Utente
- Registrato
- 8/7/12
- Messaggi
- 537
- Punti reazioni
- 15
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
E' ormai 1 mese che latita in quest'area (103-106), non sono uscite new di rilievo ma potrebbe confermare un recupero se tornasse almeno sopra 107.
Paolino967
L'AQUILA
- Registrato
- 7/1/01
- Messaggi
- 5.978
- Punti reazioni
- 176
Leggo ora che ci sono rumors che CELG comprera JUNO di cui e' gia azionista.
[$$] Celgene in Talks to Buy Juno Therapeutics
[$$] Celgene in Talks to Buy Juno Therapeutics
zerodizero
Nuovo Utente
- Registrato
- 27/1/09
- Messaggi
- 6.614
- Punti reazioni
- 147
Ho provato ad entrare diverse volte ma mi ha sempre subito messo fuori ...
Opportunita'?
Ultima modifica: